The company expects that this development could improve the strength of its application to the FDA for new drug approval
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
The company is confident of addressing all the observations within the stipulated time
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Prateek has more than 23 years of rich experience in Human Resource
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Subscribe To Our Newsletter & Stay Updated
